CNS Drugs

, Volume 28, Issue 4, pp 343–360

Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders

  • Carolina L. Haass-Koffler
  • Lorenzo Leggio
  • George A. Kenna
Review Article

Abstract

Research on the concept of craving may lead to better understanding of the biobehavioural circuitries that contribute to the complexity of alcohol use disorders (AUDs). The experiences described as craving or desire to drink are often associated with physical responses such as increased salivation and heart rate, and alteration of stress hormones, as well as psychological responses such as anxiety and depression. Greater craving has been associated with an increased probability of alcohol relapse. Reversal of craving, which is understood as a symptom of protracted abstinence, offers the possibility of preventing relapses and treating alcoholism. Various medications have been studied to establish whether they are able to reduce craving; however, the results obtained from clinical studies have been inconsistent. Here, we review the interdisciplinary models developed to evaluate craving, then the different approaches used to assess and measure craving and, finally, the medications utilized and tested to lessen craving in patients suffering from AUDs.

References

  1. 1.
    Jellinek EM. The craving for alcohol. Q J Stud Alcohol. 1955;16(1):35–8.PubMedGoogle Scholar
  2. 2.
    Anton RF. What is craving? Models and implications for treatment. Alcohol Res Health. 1999;23(3):165–73.PubMedGoogle Scholar
  3. 3.
    Anton RF, Moak DH, Latham PK. The Obsessive Compulsive Drinking Scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996;53(3):225–31.PubMedGoogle Scholar
  4. 4.
    Swift RM. Medications and alcohol craving. Alcohol Res Health. 1999;23(3):207–13.PubMedGoogle Scholar
  5. 5.
    Kenna GA, Swift RM, Hillemacher T, Leggio L. The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans. Neuropsychol Rev. 2012;22(3):211–28.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Litt MD, Cooney NL, Kadden RM, Gaupp L. Reactivity to alcohol cues and induced moods in alcoholics. Addict Behav. 1990;15(2):137–46.PubMedGoogle Scholar
  7. 7.
    Cooney NL, Litt MD, Morse PA, Bauer LO, Gaupp L. Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. J Abnorm Psychol. 1997;106(2):243–50.PubMedGoogle Scholar
  8. 8.
    Fox HC, Bergquist KL, Hong KI, Sinha R. Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals. Alcohol Clin Exp Res. 2007;31(3):395–403.PubMedGoogle Scholar
  9. 9.
    Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, et al. Stress enhancement of craving during sobriety: a risk for relapse. Alcohol Clin Exp Res. 2005;29(2):185–95.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Sinha R, Fox HC, Hong KA, Bergquist K, Bhagwagar Z, Siedlarz KM. Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology. 2009;34(5):1198–208.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Mathew RJ, Claghorn JL, Largen J. Craving for alcohol in sober alcoholics. Am J Psychiatry. 1979;136(4B):603–6.PubMedGoogle Scholar
  12. 12.
    Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM, et al. Cue exposure with coping skills treatment for male alcoholics: a preliminary investigation. J Consult Clin Psychol. 1993;61(6):1011–9.PubMedGoogle Scholar
  13. 13.
    Tiffany ST. A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Rev. 1990;97(2):147–68.PubMedGoogle Scholar
  14. 14.
    Kavanagh DJ, Statham DJ, Feeney GF, Young RM, May J, Andrade J, et al. Measurement of alcohol craving. Addict Behav. 2013;38(2):1572–84.PubMedGoogle Scholar
  15. 15.
    Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36(5):419–25.PubMedGoogle Scholar
  16. 16.
    Li TK. Clinical perspectives for the study of craving and relapse in animal models. Addiction. 2000;95(Suppl 2):S55–60.PubMedGoogle Scholar
  17. 17.
    Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O’Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999;156(1):11–8.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Kalivas PW, O’Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008;33(1):166–80.PubMedGoogle Scholar
  19. 19.
    Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl). 2003;168(1–2):3–20.PubMedGoogle Scholar
  20. 20.
    Katz JL, Higgins ST. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl). 2003;168(1–2):21–30.PubMedGoogle Scholar
  21. 21.
    Fuchs RA, Tran-Nguyen LT, Specio SE, Groff RS, Neisewander JL. Predictive validity of the extinction/reinstatement model of drug craving. Psychopharmacology (Berl). 1998;135(2):151–60.PubMedGoogle Scholar
  22. 22.
    Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, et al. Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23(8):1386–94.PubMedGoogle Scholar
  23. 23.
    Tiffany ST. Cognitive concepts of craving. Alcohol Res Health. 1999;23(3):215–24.PubMedGoogle Scholar
  24. 24.
    Bencherif B, Wand GS, McCaul ME, Kim YK, Ilgin N, Dannals RF, et al. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry. 2004;55(3):255–62.PubMedGoogle Scholar
  25. 25.
    Heinz A, Beck A, Grusser SM, Grace AA, Wrase J. Identifying the neural circuitry of alcohol craving and relapse vulnerability. Addict Biol. 2009;14(1):108–18.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Sinha R, Li CS. Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev. 2007;26(1):25–31.PubMedGoogle Scholar
  27. 27.
    Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758–64.PubMedGoogle Scholar
  28. 28.
    Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80.PubMedGoogle Scholar
  29. 29.
    O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7.PubMedGoogle Scholar
  30. 30.
    Casey M, Adamson G, Shevlin M, McKinney A. The role of craving in AUDs: dimensionality and differential functioning in the DSM-5. Drug Alcohol Depend. 2012;125(1–2):75–80.PubMedGoogle Scholar
  31. 31.
    Keyes KM, Krueger RF, Grant BF, Hasin DS. Alcohol craving and the dimensionality of alcohol disorders. Psychol Med. 2011;41(3):629–40.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Cherpitel CJ, Borges G, Ye Y, Bond J, Cremonte M, Moskalewicz J, et al. Performance of a craving criterion in DSM alcohol use disorders. J Stud Alcohol Drugs. 2010;71(5):674–84.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Mewton L, Slade T, McBride O, Grove R, Teesson M. An evaluation of the proposed DSM-5 alcohol use disorder criteria using Australian national data. Addiction. 2011;106(5):941–50.PubMedGoogle Scholar
  34. 34.
    Janca A, Ustun TB, Early TS, Sartorius N. The ICD-10 symptom checklist: a companion to the ICD-10 classification of mental and behavioural disorders. Soc Psychiatry Psychiatr Epidemiol. 1993;28(5):239–42.PubMedGoogle Scholar
  35. 35.
    Kupfer DJ, Regier DA. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am J Psychiatry. 2011;168(7):672–4.PubMedGoogle Scholar
  36. 36.
    Edwards AC, Gillespie NA, Aggen SH, Kendler KS. Assessment of a modified DSM-5 diagnosis of alcohol use disorder in a genetically informative population. Alcohol Clin Exp Res. 2013;37(3):443–51.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Haass-Koffler CL, Kenna GA. Bacchus by Caravaggio as the visual diagnosis of alcohol use disorder from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Front Psychiatry. 2013;4:86.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80.PubMedGoogle Scholar
  39. 39.
    Drummond DC, Glautier S. A controlled trial of cue exposure treatment in alcohol dependence. J Consult Clin Psychol. 1994;62(4):809–17.PubMedGoogle Scholar
  40. 40.
    Grusser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, et al. Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl). 2004;175(3):296–302.PubMedGoogle Scholar
  41. 41.
    Litt MD, Cooney NL, Morse P. Reactivity to alcohol-related stimuli in the laboratory and in the field: predictors of craving in treated alcoholics. Addiction. 2000;95(6):889–900.PubMedGoogle Scholar
  42. 42.
    Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999;34(2):197–222.PubMedGoogle Scholar
  43. 43.
    Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489–97.PubMedGoogle Scholar
  44. 44.
    Subbaraman MS, Lendle S, van der Laan M, Kaskutas LA, Ahern J. Cravings as a mediator and moderator of drinking outcomes in the COMBINE study. Addiction. 2013;14.Google Scholar
  45. 45.
    Singleton EG, Gorelick DA. Mechanisms of alcohol craving and their clinical implications. Recent Dev Alcohol. 1998;14:177–95.PubMedGoogle Scholar
  46. 46.
    Cooney NL, Gillespie RA, Baker LH, Kaplan RF. Cognitive changes after alcohol cue exposure. J Consult Clin Psychol. 1987;55(2):150–5.PubMedGoogle Scholar
  47. 47.
    Monti PM, Rohsenow DJ, Hutchison KE. Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. Addiction. 2000;95(Suppl 2):S229–36.PubMedGoogle Scholar
  48. 48.
    Mason BJ, Light JM, Williams LD, Drobes DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009;14(1):73–83.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Miranda R, Ray L, Blanchard A, Reynolds EK, Monti PM, Chun T, et al. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol. 2013. doi:10.1111/adb.12050.
  50. 50.
    Drummond DC, Litten RZ, Lowman C, Hunt WA. Craving research: future directions. Addiction. 2000;95(Suppl 2):S247–55.PubMedGoogle Scholar
  51. 51.
    Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999;34(2):197–222.PubMedGoogle Scholar
  52. 52.
    Noel X, Van Der Linden M, Bechara A. The neurocognitive mechanisms of decision-making, impulse control, and loss of willpower to resist drugs. Psychiatry (Edgmont). 2006;3(5):30–41.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Stacy AW, Wiers RW. Implicit cognition and addiction: a tool for explaining paradoxical behavior. Annu Rev Clin Psychol. 2010;6:551–75.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Field M, Munafo MR, Franken IH. A meta-analytic investigation of the relationship between attentional bias and subjective craving in substance abuse. Psychol Bull. 2009;135(4):589–607.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18(3):247–91.PubMedGoogle Scholar
  56. 56.
    Hofmann W, Schmeichel BJ, Baddeley AD. Executive functions and self-regulation. Trends Cogn Sci. 2012;16(3):174–80.PubMedGoogle Scholar
  57. 57.
    Meyer RE. Craving: what can be done to bring the insights of neuroscience, behavioral science and clinical science into synchrony. Addiction. 2000;95 Suppl 2:S219–27.Google Scholar
  58. 58.
    Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE. Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology. 2012;37(4):906–18.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278(5335):52–8.PubMedGoogle Scholar
  60. 60.
    Modell JG, Mountz JM. Focal cerebral blood flow change during craving for alcohol measured by SPECT. J Neuropsychiatry Clin Neurosci. 1995;7(1):15–22.PubMedGoogle Scholar
  61. 61.
    Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309–69.PubMedGoogle Scholar
  62. 62.
    Wise RA. The neurobiology of craving: implications for the understanding and treatment of addiction. J Abnorm Psychol. 1988;97(2):118–32.PubMedGoogle Scholar
  63. 63.
    Oak JN, Oldenhof J, Van Tol HH. The dopamine D(4) receptor: one decade of research. Eur J Pharmacol. 2000;405(1–3):303–27.PubMedGoogle Scholar
  64. 64.
    Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. 1995;65(3):1157–65.PubMedGoogle Scholar
  65. 65.
    Noain D, Avale ME, Wedemeyer C, Calvo D, Peper M, Rubinstein M. Identification of brain neurons expressing the dopamine D4 receptor gene using BAC transgenic mice. Eur J Neurosci. 2006;24(9):2429–38.PubMedGoogle Scholar
  66. 66.
    Katner SN, Weiss F. Neurochemical characteristics associated with ethanol preference in selected alcohol-preferring and -nonpreferring rats: a quantitative microdialysis study. Alcohol Clin Exp Res. 2001;25(2):198–205.PubMedGoogle Scholar
  67. 67.
    Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171–91.PubMedGoogle Scholar
  68. 68.
    Melendez RI, Rodd-Henricks ZA, Engleman EA, Li TK, McBride WJ, Murphy JM. Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol. Alcohol Clin Exp Res. 2002;26(3):318–25.PubMedGoogle Scholar
  69. 69.
    Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron. 2005;45(5):647–50.PubMedGoogle Scholar
  70. 70.
    Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grusser SM, et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry. 2004;161(10):1783–9.PubMedGoogle Scholar
  71. 71.
    Heinz A, Lober S, Georgi A, Wrase J, Hermann D, Rey ER, et al. Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol. 2003;38(1):35–9.PubMedGoogle Scholar
  72. 72.
    LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry. 1994;36(5):326–37.PubMedGoogle Scholar
  73. 73.
    Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept—an hypothesis. Alcohol Clin Exp Res. 2000;24(10):1597–601.PubMedGoogle Scholar
  74. 74.
    Modell JG, Glaser FB, Cyr L, Mountz JM. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res. 1992;16(2):272–4.PubMedGoogle Scholar
  75. 75.
    Roberts JS, Anton RF, Latham PK, Moak DH. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999;23(9):1484–91.PubMedGoogle Scholar
  76. 76.
    Lovinger DM, Zhou Q. Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology. 1994;33(12):1567–72.PubMedGoogle Scholar
  77. 77.
    Pandey SC, Davis JM, Pandey GN. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci. 1995;20(3):215–25.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Ciccocioppo R. The role of serotonin in craving: from basic research to human studies. Alcohol Alcohol. 1999;34(2):244–53.PubMedGoogle Scholar
  79. 79.
    Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol. 1998;12(1):54–67.PubMedGoogle Scholar
  80. 80.
    Lal H, Prather PL, Rezazadeh SM. Potential role of 5HT1C and/or 5HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res. 1993;17(2):411–7.PubMedGoogle Scholar
  81. 81.
    Lovinger DM. 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic. Neurochem Int. 1999;35(2):125–30.PubMedGoogle Scholar
  82. 82.
    Di Chiara G, Imperato A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol. 1985;115(1):131–2.PubMedGoogle Scholar
  83. 83.
    Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 2005;62(1):57–64.PubMedGoogle Scholar
  84. 84.
    Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci. 2001;26(4):304–18.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Koob GF, Weiss F, Tiffany ST, Zieglgansberger W, Spanagel R. Animal models of craving: a roundtable discussion. Alcohol Res Health. 1999;23(3):233–6.PubMedGoogle Scholar
  86. 86.
    Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav. 2005;84(1):53–63.PubMedGoogle Scholar
  87. 87.
    Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28(10):1882–8.PubMedGoogle Scholar
  88. 88.
    Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069–77.PubMedGoogle Scholar
  89. 89.
    Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546–52.PubMedGoogle Scholar
  90. 90.
    Brown SA, Vik PW, McQuaid JR, Patterson TL, Irwin MR, Grant I. Severity of psychosocial stress and outcome of alcoholism treatment. J Abnorm Psychol. 1990;99(4):344–8.PubMedGoogle Scholar
  91. 91.
    Breese GR, Knapp DJ, Overstreet DH. Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT1A-receptor agonist. Neuropsychopharmacology. 2004;29(3):470–82.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77(5):479–87.PubMedGoogle Scholar
  93. 93.
    Sitharthan T, McGrath D, Sitharthan G, Saunders JB. Meaning of craving in research on addiction. Psychol Rep. 1992;71(3 Pt 1):823–6.PubMedGoogle Scholar
  94. 94.
    Drobes DJ, Thomas SE. Assessing craving for alcohol. Alcohol Res Health. 1999;23(3):179–86.PubMedGoogle Scholar
  95. 95.
    Ooteman W, Koeter MW, Vserheul R, Schippers GM, van den Brink W. Measuring craving: an attempt to connect subjective craving with cue reactivity. Alcohol Clin Exp Res. 2006;30(1):57–69.PubMedGoogle Scholar
  96. 96.
    Connor JP, Feeney GF, Young RM. A comparison of the Yale–Brown Obsessive Compulsive Scale for “heavy drinking” with a single item craving measure: construct validity and clinical utility. Subst Use Misuse. 2005;40(4):551–61.PubMedGoogle Scholar
  97. 97.
    Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289–95.PubMedGoogle Scholar
  98. 98.
    Modell JG, Glaser FB, Mountz JM, Schmaltz S, Cyr L. Obsessive and compulsive characteristics of alcohol abuse and dependence: quantification by a newly developed questionnaire. Alcohol Clin Exp Res. 1992;16(2):266–71.PubMedGoogle Scholar
  99. 99.
    Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19(1):92–9.PubMedGoogle Scholar
  100. 100.
    Anton RF. Obsessive–compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction. 2000;95(Suppl 2):S211–7.PubMedGoogle Scholar
  101. 101.
    Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19(3):600–6.PubMedGoogle Scholar
  102. 102.
    Kavanagh DJ, Andrade J, May J. Imaginary relish and exquisite torture: the elaborated intrusion theory of desire. Psychol Rev. 2005;112(2):446–67.PubMedGoogle Scholar
  103. 103.
    Kavanagh DJ, May J, Andrade J. Tests of the elaborated intrusion theory of craving and desire: features of alcohol craving during treatment for an alcohol disorder. Br J Clin Psychol. 2009;48(Pt 3):241–54.PubMedGoogle Scholar
  104. 104.
    Statham DJ, Connor JP, Kavanagh DJ, Feeney GF, Young RM, May J, et al. Measuring alcohol craving: development of the Alcohol Craving Experience questionnaire. Addiction. 2011;106(7):1230–8.PubMedGoogle Scholar
  105. 105.
    Cacioppo JT, Martzke JS, Petty RE, Tassinary LG. Specific forms of facial EMG response index emotions during an interview: from Darwin to the continuous flow hypothesis affect-laden information processing. J Pers Soc Psychol. 1988;54(4):592–604.PubMedGoogle Scholar
  106. 106.
    Drobes DJ, Tiffany ST. Induction of smoking urge through imaginal and in vivo procedures: physiological and self-report manifestations. J Abnorm Psychol. 1997;106(1):15–25.PubMedGoogle Scholar
  107. 107.
    Everitt B. Craving cocaine cues: cognitive neuroscience meets drug addiction research. Trends Cogn Sci. 1997;1(1):1–2.PubMedGoogle Scholar
  108. 108.
    Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008;65(4):466–75.PubMedCentralPubMedGoogle Scholar
  109. 109.
    Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587–93.PubMedGoogle Scholar
  110. 110.
    O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo–pituitary–adrenocortical axis. Psychopharmacology (Berl). 2002;160(1):19–29.PubMedGoogle Scholar
  111. 111.
    Davidson D, Palfai T, Bird C, Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res. 1999;23(2):195–203.PubMedGoogle Scholar
  112. 112.
    Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O’Brien CP, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10(3):258–68.PubMedGoogle Scholar
  113. 113.
    Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, et al. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49(8):599–608.PubMedGoogle Scholar
  114. 114.
    Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O’Malley SS. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol. 1996;64(5):1044–53.PubMedGoogle Scholar
  115. 115.
    O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49(11):881–7.PubMedGoogle Scholar
  116. 116.
    Volpicelli JR, Clay KL, Watson NT, O’Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry. 1995;56(Suppl 7):39–44.PubMedGoogle Scholar
  117. 117.
    Kranzler HR, Tennen H, Penta C, Bohn MJ. Targeted naltrexone treatment of early problem drinkers. Addict Behav. 1997;22(3):431–6.PubMedGoogle Scholar
  118. 118.
    Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287–92.PubMedGoogle Scholar
  119. 119.
    Mann K, Bladstrom A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–13.PubMedGoogle Scholar
  120. 120.
    Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349–57.PubMedGoogle Scholar
  121. 121.
    Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, et al. Posttreatment results of combining naltrexone with cognitive–behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol. 2001;21(1):72–7.PubMedGoogle Scholar
  122. 122.
    Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758–64.PubMedGoogle Scholar
  123. 123.
    Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006;111(3):855–76.PubMedGoogle Scholar
  124. 124.
    Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol. 2006;26(Suppl 1):S37–42.PubMedGoogle Scholar
  125. 125.
    Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. JAMA. 2006;295(17):2003–17.PubMedGoogle Scholar
  126. 126.
    De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol. 2004;39(6):528–31.PubMedGoogle Scholar
  127. 127.
    Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734–9.PubMedGoogle Scholar
  128. 128.
    Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley SS. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry. 2007;62(6):694–7.PubMedGoogle Scholar
  129. 129.
    McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30(8):1288–96.PubMedGoogle Scholar
  130. 130.
    Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135–44.PubMedCentralPubMedGoogle Scholar
  131. 131.
    Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007;31(4):555–63.PubMedGoogle Scholar
  132. 132.
    Kranzler HR, Armeli S, Covault J, Tennen H. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. 2013;18(1):193–201.PubMedCentralPubMedGoogle Scholar
  133. 133.
    Modell JG, Mountz JM, Beresford TP. Basal ganglia/limbic striatal and thalamocortical involvement in craving and loss of control in alcoholism. J Neuropsychiatry Clin Neurosci. 1990;2(2):123–44.PubMedGoogle Scholar
  134. 134.
    Modell JG, Mountz JM, Glaser FB, Lee JY. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res. 1993;17(2):234–40.PubMedGoogle Scholar
  135. 135.
    Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23(3 Suppl 1):S21–6.PubMedGoogle Scholar
  136. 136.
    Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60(11):767–70.PubMedGoogle Scholar
  137. 137.
    Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64(5):575–9.PubMedGoogle Scholar
  138. 138.
    Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl). 2001;155(1):27–34.PubMedGoogle Scholar
  139. 139.
    Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol. 2007;27(4):344–51.PubMedCentralPubMedGoogle Scholar
  140. 140.
    Scheller-Gilkey G, Woolwine BJ, Cooper I, Gay O, Moynes KA, Miller AH. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse. 2003;29(3):553–66.PubMedGoogle Scholar
  141. 141.
    Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60(1):81–5.PubMedGoogle Scholar
  142. 142.
    Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyurek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol. 2005;19(3):301–5.PubMedGoogle Scholar
  143. 143.
    Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26(2):441–9.PubMedGoogle Scholar
  144. 144.
    Kenna GA. Rationale for use of aripiprazole for alcohol dependence treatment. Drugs Future. 2003;28(12):1227–35.Google Scholar
  145. 145.
    Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1):5–12.PubMedGoogle Scholar
  146. 146.
    Martinotti G, Di Nicola M, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse. 2007;33(3):393–401.PubMedGoogle Scholar
  147. 147.
    Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23(2):123–9.PubMedGoogle Scholar
  148. 148.
    Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(5):532–5.PubMedGoogle Scholar
  149. 149.
    Landolt HP, Gillin JC. Sleep abnormalities during abstinence in alcohol-dependent patients: aetiology and management. CNS Drugs. 2001;15(5):413–25.PubMedGoogle Scholar
  150. 150.
    Croissant B, Klein O, Gehrlein L, Kniest A, Hermann D, Diehl A, et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry. 2006;21(8):570–3.PubMedGoogle Scholar
  151. 151.
    Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;23(5):417–24.PubMedGoogle Scholar
  152. 152.
    Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(3):406–16.PubMedCentralPubMedGoogle Scholar
  153. 153.
    Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31(6):1310–7.PubMedGoogle Scholar
  154. 154.
    Agrawal A, Wetherill L, Bucholz KK, Kramer J, Kuperman S, Lynskey MT, et al. Genetic influences on craving for alcohol. Addict Behav. 2013;38(2):1501–8.PubMedCentralPubMedGoogle Scholar
  155. 155.
    Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284(8):963–71.PubMedGoogle Scholar
  156. 156.
    Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl). 2002;160(4):408–13.PubMedGoogle Scholar
  157. 157.
    Myrick H, Anton RF, Li X, Henderson S, Drobes D, Voronin K, et al. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. 2004;29(2):393–402.PubMedGoogle Scholar
  158. 158.
    Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol. 1994;9(3):163–72.PubMedGoogle Scholar
  159. 159.
    Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res. 1996;20(4):780–4.PubMedGoogle Scholar
  160. 160.
    Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry. 2001;62(Suppl 20):26–31.PubMedGoogle Scholar
  161. 161.
    Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21(2):143–53.PubMedGoogle Scholar
  162. 162.
    Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive–behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20(9):1534–41.PubMedGoogle Scholar
  163. 163.
    Lovinger DM. Serotonin’s role in alcohol’s effects on the brain. Alcohol Health Res World. 1997;21(2):114–20.PubMedGoogle Scholar
  164. 164.
    Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 2. Am J Health Syst Pharm. 2004;61(22):2380–8.PubMedGoogle Scholar
  165. 165.
    Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24(7):1041–9.PubMedGoogle Scholar
  166. 166.
    Johnson BA. The role of serotonergic agents as treatments for alcoholism. Drugs Today (Barc). 2003;39(9):665–72.PubMedGoogle Scholar
  167. 167.
    Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 2013;170(9):1020–31.PubMedGoogle Scholar
  168. 168.
    Johnson BA, Ait-Daoud N, Ma JZ, Wang Y. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol Clin Exp Res. 2003;27(11):1773–9.PubMedGoogle Scholar
  169. 169.
    Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res. 2009;33(2):315–23.PubMedGoogle Scholar
  170. 170.
    Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011;31(1):22–30.PubMedCentralPubMedGoogle Scholar
  171. 171.
    Ait-Daoud N, Seneviratne C, Smith JB, Roache JD, Dawes MA, Liu L, et al. Preliminary evidence for cue-induced alcohol craving modulated by serotonin transporter gene polymorphism rs1042173. Front Psychiatry. 2012;3:6.PubMedCentralPubMedGoogle Scholar
  172. 172.
    Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641–51.PubMedGoogle Scholar
  173. 173.
    Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–85.PubMedGoogle Scholar
  174. 174.
    Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122–9.PubMedCentralPubMedGoogle Scholar
  175. 175.
    Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007;30(4):230–40.PubMedGoogle Scholar
  176. 176.
    Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat. 2009;5:467–76.PubMedCentralPubMedGoogle Scholar
  177. 177.
    Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol. 1997;12(Suppl 1):S2–9.PubMedGoogle Scholar
  178. 178.
    Vengeliene V, Heidbreder CA, Spanagel R. The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology. 2007;53(8):951–7.PubMedGoogle Scholar
  179. 179.
    Sarid-Segal O, Piechniczek-Buczek J, Knapp C, Afshar M, Devine E, Sickles L, et al. The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse. 2008;34(4):441–7.PubMedGoogle Scholar
  180. 180.
    Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(8):1421–30.PubMedCentralPubMedGoogle Scholar
  181. 181.
    Rubio G, Lopez-Munoz F, Ferre F, Martinez-Gras I, Ponce G, Pascual JM, et al. Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol. 2010;33(5):250–3.PubMedGoogle Scholar
  182. 182.
    Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol. 2010;30(3):318–22.PubMedCentralPubMedGoogle Scholar
  183. 183.
    Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002;112(3):226–9.PubMedGoogle Scholar
  184. 184.
    Addolorato G, Leggio L, Abenavoli L, Caputo F, Gasbarrini G. Baclofen for outpatient treatment of alcohol withdrawal syndrome. J Fam Pract. 2005;54(1):24.PubMedGoogle Scholar
  185. 185.
    Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006;119(3):276 e13–8.Google Scholar
  186. 186.
    Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–22.PubMedGoogle Scholar
  187. 187.
    Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37(4):561–4.PubMedGoogle Scholar
  188. 188.
    Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med. 2011;6(8):469–74.PubMedGoogle Scholar
  189. 189.
    Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II—preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24(1):67–71.PubMedGoogle Scholar
  190. 190.
    Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504–8.PubMedGoogle Scholar
  191. 191.
    Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 2007;42(2):158–60.PubMedGoogle Scholar
  192. 192.
    Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004;28(10):1517–23.PubMedGoogle Scholar
  193. 193.
    Drake RG, Davis LL, Cates ME, Jewell ME, Ambrose SM, Lowe JS. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother. 2003;37(9):1177–81.PubMedGoogle Scholar
  194. 194.
    Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807–16.PubMedGoogle Scholar
  195. 195.
    Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849–57.PubMedCentralPubMedGoogle Scholar
  196. 196.
    Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9(1):33–44.Google Scholar
  197. 197.
    Colloca L, Miller FG. How placebo responses are formed: a learning perspective. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1859–69.PubMedCentralPubMedGoogle Scholar
  198. 198.
    Marsot A, Imbert B, Alvarez JC, Grassin-Delyle S, Jaquet I, Lancon C, et al. High variability in the exposure of baclofen in alcohol-dependent patients. Alcohol Clin Exp Res. 2014;38(2):316–21.Google Scholar
  199. 199.
    Leggio L, Zywiak WH, McGeary JE, Edwards S, Fricchione SR, Shoaff JR, et al. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav. 2013;103(4):784–91.PubMedGoogle Scholar
  200. 200.
    Johnson BA, Swift RM, Addolorato G, Ciraulo DA, Myrick H. Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin Exp Res. 2005;29(2):248–54.Google Scholar
  201. 201.
    Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 1992;16(4):673–6.PubMedGoogle Scholar
  202. 202.
    Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol. 1996;31(4):341–5.PubMedGoogle Scholar
  203. 203.
    Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol. 1992;34(3):231–5.PubMedCentralPubMedGoogle Scholar
  204. 204.
    Addolorato G, Cibin M, Caputo F, Capristo E, Gessa GL, Stefanini GF, et al. Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug Alcohol Depend. 1998;53(1):7–10.PubMedGoogle Scholar
  205. 205.
    Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini A. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs. 2009;18(5):675–86.PubMedGoogle Scholar
  206. 206.
    Weight FF. Cellular and molecular physiology of alcohol actions in the nervous system. Int Rev Neurobiol. 1992;33:289–348.PubMedGoogle Scholar
  207. 207.
    Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science. 1989;243(4899):1721–4.PubMedGoogle Scholar
  208. 208.
    Peoples RW, Weight FF. Ethanol inhibition of N-methyl-d-aspartate-activated ion current in rat hippocampal neurons is not competitive with glycine. Brain Res. 1992;571(2):342–4.PubMedGoogle Scholar
  209. 209.
    Lovinger DM. Developmental decrease in ethanol inhibition of N-methyl-d-aspartate receptors in rat neocortical neurons: relation to the actions of ifenprodil. J Pharmacol Exp Ther. 1995;274(1):164–72.PubMedGoogle Scholar
  210. 210.
    Grant KA, Colombo G. Discriminative stimulus effects of ethanol: effect of training dose on the substitution of N-methyl-d-aspartate antagonists. J Pharmacol Exp Ther. 1993;264(3):1241–7.PubMedGoogle Scholar
  211. 211.
    Hundt W, Danysz W, Holter SM, Spanagel R. Ethanol and N-methyl-d-aspartate receptor complex interactions: a detailed drug discrimination study in the rat. Psychopharmacology (Berl). 1998;135(1):44–51.PubMedGoogle Scholar
  212. 212.
    Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55(4):354–60.PubMedGoogle Scholar
  213. 213.
    Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry. 2007;164(3):519–23.PubMedGoogle Scholar
  214. 214.
    Bienkowski P, Koros E, Kostowski W, Danysz W. Effects of N-methyl-d-aspartate receptor antagonists on reinforced and nonreinforced responding for ethanol in rats. Alcohol. 1999;18(2–3):131–7.PubMedGoogle Scholar
  215. 215.
    Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl). 2004;172(1):16–24.PubMedGoogle Scholar
  216. 216.
    Nagy J. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? IDrugs. 2004;7(4):339–50.PubMedGoogle Scholar
  217. 217.
    Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31(5):775–82.PubMedGoogle Scholar
  218. 218.
    De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19(6):517–37.PubMedGoogle Scholar
  219. 219.
    Blednov YA, Harris RA. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol. 2008;11(6):775–93.PubMedCentralPubMedGoogle Scholar
  220. 220.
    Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28(1):51–63.PubMedGoogle Scholar
  221. 221.
    Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;1(8436):1014–6.PubMedGoogle Scholar
  222. 222.
    Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239–47.PubMedGoogle Scholar
  223. 223.
    Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73–7.PubMedGoogle Scholar
  224. 224.
    Hammarberg A, Nylander I, Zhou Q, Jayaram-Lindstrom N, Reid MS, Franck J. The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. Brain Res. 2009;1305(Suppl):S2–6.PubMedGoogle Scholar
  225. 225.
    Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J. 2011;11(5):368–74.PubMedGoogle Scholar
  226. 226.
    Savas MC, Gullu IH. Disulfiram-ethanol test reaction: significance of supervision. Ann Pharmacother. 1997;31(3):374–5.PubMedGoogle Scholar
  227. 227.
    Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26(3):290–302.PubMedGoogle Scholar
  228. 228.
    de Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2005;40(6):545–8.PubMedGoogle Scholar
  229. 229.
    Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57(10):1128–37.PubMedGoogle Scholar
  230. 230.
    Rogers WK, Benowitz NL, Wilson KM, Abbott JA. Effect of disulfiram on adrenergic function. Clin Pharmacol Ther. 1979;25(4):469–77.PubMedGoogle Scholar
  231. 231.
    Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry. 2006;60(7):777–83.PubMedGoogle Scholar
  232. 232.
    Karamanakos PN, Pappas P, Stephanou P, Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol Toxicol. 2001;88(2):106–10.PubMedGoogle Scholar
  233. 233.
    Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des. 2010;16(19):2076–90.PubMedGoogle Scholar
  234. 234.
    Franck J, Jayaram-Lindstrom N. Pharmacotherapy for alcohol dependence: status of current treatments. Curr Opin Neurobiol. 2013;23(4):692–9.Google Scholar
  235. 235.
    Tizabi Y, Bai L, Copeland RL Jr, Taylor RE. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol. 2007;42(5):413–6.PubMedGoogle Scholar
  236. 236.
    Chatterjee S, Bartlett SE. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol Disord Drug Targets. 2010;9(1):60–76.PubMedCentralPubMedGoogle Scholar
  237. 237.
    Ericson M, Lof E, Stomberg R, Soderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther. 2009;329(1):225–30.PubMedGoogle Scholar
  238. 238.
    Bito-Onon JJ, Simms JA, Chatterjee S, Holgate J, Bartlett SE. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague–Dawley rats. Addict Biol. 2011;16(3):440–9.PubMedCentralPubMedGoogle Scholar
  239. 239.
    Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA. 2007;104(30):12518–23.PubMedCentralPubMedGoogle Scholar
  240. 240.
    Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl). 2012;223(3):299–306.PubMedCentralPubMedGoogle Scholar
  241. 241.
    Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011;215(4):655–63.PubMedCentralPubMedGoogle Scholar
  242. 242.
    Wouda JA, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D, et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl). 2011;216(2):267–77.PubMedCentralPubMedGoogle Scholar
  243. 243.
    McKee SA, Harrison EL, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66(2):185–90.PubMedCentralPubMedGoogle Scholar
  244. 244.
    Plebani JG, Lynch KG, Rennert L, Pettinati HM, O’Brien CP, Kampman KM. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend. 2013;133(2):754–8.PubMedGoogle Scholar
  245. 245.
    Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277–286.Google Scholar
  246. 246.
    Le AD, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C, et al. Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology (Berl). 2011;218(1):89–99.PubMedCentralPubMedGoogle Scholar
  247. 247.
    Walker BM, Rasmussen DD, Raskind MA, Koob GF. Alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol. 2008;42(2):91–7.PubMedCentralPubMedGoogle Scholar
  248. 248.
    Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC. The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res. 2009;33(2):264–72.PubMedCentralPubMedGoogle Scholar
  249. 249.
    Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, et al. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res. 2012;36(2):351–60.PubMedCentralPubMedGoogle Scholar
  250. 250.
    Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009;33(2):255–63.PubMedGoogle Scholar
  251. 251.
    Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT, et al. Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev. 2010;35(2):334–44.PubMedCentralPubMedGoogle Scholar
  252. 252.
    Gehlert DR, Cramer J, Morin SM. Effects of corticotropin-releasing factor 1 receptor antagonism on the hypothalamic–pituitary–adrenal axis of rodents. J Pharmacol Exp Ther. 2012;341(3):672–80.PubMedGoogle Scholar
  253. 253.
    Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, et al. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci. 2007;27(10):2718–26.PubMedGoogle Scholar
  254. 254.
    Zorrilla EP, Heilig M, de Wit H, Shaham Y. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013;128(3):175–86.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Carolina L. Haass-Koffler
    • 1
  • Lorenzo Leggio
    • 1
    • 2
    • 3
  • George A. Kenna
    • 1
    • 4
  1. 1.Center for Alcohol and Addiction StudiesBrown UniversityProvidenceUSA
  2. 2.Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Laboratory of Clinical and Translational Studies (LCTS)National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH)BethesdaUSA
  3. 3.Intramural Research ProgramNational Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)BaltimoreUSA
  4. 4.Department of Psychiatry and Human BehaviorBrown UniversityProvidenceUSA

Personalised recommendations